[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336494-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336494-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-panel-sequencing-dataset-of-peripheral-blood-gene-variations-in-pan-cancer-database-construction-and-panel-sequencing-results","A panel sequencing dataset of peripheral blood gene variations in pan-cancer - Database construction and panel sequencing results","","Circulating cell-free DNA (cfDNA) from peripheral blood is highlighted as a promising biomarker for cancer diagnosis and prognosis, motivating the need to jointly analyze germline variants and somatic mutations across multiple cancer types. This study performs panel sequencing covering 1,115 cancer-related genes across 16,659 cancer patients from 27 cancer types, identifying 496 germline variants and 11,232 somatic mutations in cfDNA. From these results, CPGV is built as a pan-cancer cfDNA database integrating both mutation classes and comparative analyses to support cancer research.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-panel-sequencing-dataset-of-peripheral-blood-gene-variations-in-pan-cancer-database-construction-and-panel-sequencing-results/336494/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-panel-sequencing-dataset-of-peripheral-blood-gene-variations-in-pan-cancer-database-construction-and-panel-sequencing-results/336494.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What data does the study generate for pan-cancer peripheral blood mutations?","Question",{"text":63,"@type":64},"The work performs panel sequencing of 1,115 cancer-related genes across 16,659 patients spanning 27 cancer types, yielding both germline variants and somatic mutations from peripheral-blood cfDNA.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are germline variants and somatic mutations used in the resulting resource?",{"text":68,"@type":64},"The database named CPGV integrates germline variants (from leukocytes) and somatic mutations (from cfDNA) and provides comparative analyses across different cancer types.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is cfDNA considered useful for cancer analysis and monitoring?",{"text":72,"@type":64},"Because cfDNA is a degraded DNA fragment released into plasma, it can reflect a broad view of the tumor genome, help address intratumor heterogeneity, and support screening, diagnosis, and monitoring.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336494,1790211930,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","[www. nature.com/scientificdata](www. nature.com/scientificdata)  \noPeN  \nDAtA DeSCrIPtor  \na panel sequencing dataset of peripheral blood gene variations in pan-cancer  \nYanxia Liu1,2,8, Jie Liu3,8, Shouwei Zhang4, Jinyue Wang2,5, Zhihong Sun3, Huaibo Sun4, YingYang4, Guangmin Zheng1,2,6, Yu Huang4, Meng Li1,2,7, Zhaojun Zhang1,2,6,7, Jingfa Xiao1,2,5,6, Changqing Zeng1,2,6, Chengming Sun3 ✉, Hongzhu Qu1,2,6,7 ✉ & Xiangdong Fang1,2,6,7 ✉  \nCirculating cell-free DNA (cfDNA) in the peripheral blood is a promising biomarker for cancer diagnosis and prognosis. Somatic mutations identified in cancers have been used to detect therapeutic targets for clinical transformation and individualize drug selection, while germline variants can predict a patient’s risk of developing cancer and drug sensitivity. However, no platform has been developed to analyze, calculate, integrate, and friendly visualize these pan-cancer cfDNA mutations deeply. In this work, we performed panel sequencing encompassing 1,115 cancer-related genes across 16,659 cancer patients, spanning 27 cancer types. We detected 496 germline variants in leukocytes and 11,232 somatic mutations in the cfDNA ofall patients. CPGV (Cancer Peripheral blood Gene Variations), a database constructed from this dataset, is the first pan-cancer cfDNA database that encompasses somatic mutations, germline variants, and further comparative analyses of mutations across different cancer types. It bears great promise to serve as a valuable resource for cancer research.  \nBackground & Summary  \nLarge-scale sequencing projects have dramatically enhanced our molecular understanding of cancers to the point where using genomic analysis to improve treatment outcomes seems promising 1–4. A pan-cancer atlas provides a panoramic view of the oncogenic processes that contribute to human cancer, featuring hundreds of predisposing germline variants identified and linked to functional consequences, thus providing guidelines for variant classification and germline genetic testing in cancer5–8. Actionable genetic alterations in signaling pathways provide opportunities for targeted and combination therapies9–11. In addition, pan-cancer analysis will enable effective therapies in one cancer type to be extended to other types with similar genomic profiles12. Therefore, pan-cancer mutation resources are valuable for cancer research and medical care.  \nCell-free DNA (cfDNA) is a degraded DNA fragment which is released into the plasma; therefore, it can provide a panoramic view of the tumor genome, overcome intratumor heterogeneity issues, and can be used for cancer screening, diagnosis, and monitoring13–16. With the development of sequencing technology, the sensitivity and accuracy of cfDNA genotyping have greatly improved. Due to its characteristics of non-invasive sampling and easy-to-obtain, cfDNA has become a potential molecule that has attracted much attention for clinical transformation17–20. In recent years, an increasing number of studies related to cfDNA have been published, which have provided great help in the treatment of tumors21–25. Subsequently, a comprehensive database of cfDNA fragmentation was created26. However, no database or platform has been developed to integrate germline variants and somatic mutation data from pan-cancer peripheral blood.  \nTo address this gap, we developed a comprehensive resource, named CPGV, to integrate gene variations from pan-cancer peripheral blood samples. CPGV would serve as an invaluable resource for cancer research.  \n1China National Center for Bioinformation, Beijing, 100101, China. 2Beijing institute of Genomics, chinese Academy of Sciences, Beijing, 100101, China. 3Yantai Yuhuangding Hospital, Yantai, 264000, China. 4Genecast Biotechnology Co., Ltd, Wuxi, 214104, China. 5national Genomics Data center, china national center for Bioinformation, Beijing, 100101, China. 6 University of Chinese Academy of Sciences, Beijing, 100049, China. 7 Beijing Key Laboratory ","cbCaimUCxTNG2GMB","https://ap.wps.com/l/cbCaimUCxTNG2GMB","pdf",2469006,"English","# Background & Summary\n# Methods\n## Database construction\n## Sample collection\n## DNA extraction, sequencing, and data processing","[{\"question\":\"What data does the study generate for pan-cancer peripheral blood mutations?\",\"answer\":\"The work performs panel sequencing of 1,115 cancer-related genes across 16,659 patients spanning 27 cancer types, yielding both germline variants and somatic mutations from peripheral-blood cfDNA.\"},{\"question\":\"How are germline variants and somatic mutations used in the resulting resource?\",\"answer\":\"The database named CPGV integrates germline variants (from leukocytes) and somatic mutations (from cfDNA) and provides comparative analyses across different cancer types.\"},{\"question\":\"Why is cfDNA considered useful for cancer analysis and monitoring?\",\"answer\":\"Because cfDNA is a degraded DNA fragment released into plasma, it can reflect a broad view of the tumor genome, help address intratumor heterogeneity, and support screening, diagnosis, and monitoring.\"}]","A panel sequencing dataset of peripheral blood gene variations in pan-cancer - Database construction and panel sequencing results | PDF",1790015332,18,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a2f0f91d8d295d8c87681b7c0431c7be.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/466f6b46ede7f1598cda862866bbd1ac.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ce571082e4dca3a33d08e17759d76586.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/daecc6ef7a808c7a1103666dbd0cbdca.webp",980,1287]